Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  dabrafenib
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1161, NCI-2013-02381, NCT02027961
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20120238, NCI-2014-01974, NCT02110355
Ipilimumab and Dabrafenib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: HCI68132, NCI-2014-02564, CA184-371, IDM, IRB # 68132, NCT02200562
Dabrafenib, Trametinib, and Navitoclax in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-424, NCI-2013-02103, NCT01970956, 9466, NCT01989585
Dabrafenib in Treating Patients with Stage IIIC Melanoma That Has Been Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: 12-124, NCI-2012-01706, NCT01682213
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: MEL-1263, NCI-2012-01699, 2011N129968_00, VICC MEL 1263, NCT01701037
Dabrafenib and Stereotactic Radiosurgery in Treating Patients With Melanoma and Brain Metastases
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC # 12857, NCI-2012-02214, NCT01721603
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Dabrafenib and Trametinib in Treating Patients with Stage III-IV Melanoma That Cannot be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1128, NCI-2013-01061, NCT01726738
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116833, NCI-2014-00142, NCT01750918
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116521, NCI-2014-01364, NCT01978236
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117277, NCI-2014-01207, NCT02039947
Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1320, NCI-2014-01470, NCT02196181
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-Q, EAY131-R, EAY131-U, EAY131-V, NCT02465060
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 114144, NCI-2011-02757, NCT01231594
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 month to 17 years
Trial IDs: 116013, NCI-2013-00631, NCT01677741
Dabrafenib in Treating Patients with Solid Tumors and Kidney or Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1211, NCI-2013-01338, 9343, NCT01907802
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-061, NCI-2013-01748, 9354, NCT01947023
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients with Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-186, NCI-2014-00615, 9557, NCT02097225
Start Over